Payment overview · 2025
General Payments
$2,584.09
65 reported records · 18 companies
Healthcare provider profile · identity verified
Daniel Jimenez, MD
Allopathic & Osteopathic Physicians|Family Medicine · SANTA ANA, CA · NPI 1255466801
Verified facts
What the public records show
CMS Open Payments records show Daniel Jimenez, MD received $2,584.09 in general payments during 2025 across 65 reported records.
AstraZeneca Pharmaceuticals LP accounted for 20.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $517.12 | 20.0% | 12 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $364.38 | 14.1% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $354.83 | 13.7% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $273.00 | 10.6% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $224.83 | 8.7% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $159.75 | 6.2% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $145.49 | 5.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $143.18 | 5.5% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $105.48 | 4.1% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $79.34 | 3.1% | 3 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $34.36 | 1.3% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $31.55 | 1.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.21 | 1.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $28.27 | 1.1% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $25.40 | 1.0% | 1 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $24.17 | 0.9% | 1 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $23.06 | 0.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.67 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,584.09 | 65 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $364.38 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $313.91 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $309.77 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $232.76 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $225.46 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $159.75 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $153.02 | 6 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $145.49 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $122.07 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $119.76 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $116.44 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $105.07 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $100.46 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $79.34 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $56.08 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $46.54 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $34.36 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $31.55 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $29.21 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $28.27 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $26.74 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $25.40 | 1 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $24.17 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.59 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.59 | 1 | 2025 |
Source payment records
|
|||||
| UROLIFT Normalized: urolift |
Device | Teleflex LLC | $23.06 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 68 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 106 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 138 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 57 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 74 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 65 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
28 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
106 | 39 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
138 | 43 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
138 | 43 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
57 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
89 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
74 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
65 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
68 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 628 | 210 |
| Metformin Hcl | Metformin Hcl | 548 | 167 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 533 | 176 |
| Amlodipine Besylate | Amlodipine Besylate | 378 | 121 |
| Levothyroxine Sodium | Levothyroxine Sodium | 341 | 105 |
| Lisinopril | Lisinopril | 300 | 91 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 277 | 64 |
| Losartan Potassium | Losartan Potassium | 242 | 78 |
| Tamsulosin Hcl | Tamsulosin Hcl | 226 | 74 |
| Omeprazole | Omeprazole | 195 | 94 |
| Valsartan | Valsartan | 192 | 70 |
| Pioglitazone Hcl | Pioglitazone Hcl | 191 | 67 |
| Diclofenac Sodium | Diclofenac Sodium | 182 | 68 |
| Gabapentin | Gabapentin | 172 | 64 |
| Jardiance | Empagliflozin | 138 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 136 | 38 |
| Famotidine | Famotidine | 135 | 50 |
| Furosemide | Furosemide | 123 | 40 |
| Ketoconazole | Ketoconazole | 123 | 55 |
| Tramadol Hcl | Tramadol Hcl | 111 | 32 |
| Farxiga | Dapagliflozin Propanediol | 106 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 104 | 51 |
| Vascepa | Icosapent Ethyl | 104 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 52 |
| Benazepril Hcl | Benazepril Hcl | 102 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 95 | 24 |
| Mirtazapine | Mirtazapine | 95 | 39 |
| Alendronate Sodium | Alendronate Sodium | 90 | 32 |
| Trulicity | Dulaglutide | 89 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 34 |
| Potassium Chloride | Potassium Chloride | 85 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 39 |
| Metformin Hcl Er | Metformin Hcl | 82 | 28 |
| Nifedipine Er | Nifedipine | 82 | 23 |
| Myrbetriq | Mirabegron | 81 | 37 |
| Azithromycin | Azithromycin | 80 | 70 |
| Ibuprofen | Ibuprofen | 79 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 76 | 25 |
| Carvedilol | Carvedilol | 75 | 19 |
| Alprazolam | Alprazolam | 74 | 25 |
| Ozempic | Semaglutide | 74 | 26 |
| Finasteride | Finasteride | 69 | 24 |
| Eliquis | Apixaban | 68 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 20 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 67 | 35 |
| Simvastatin | Simvastatin | 67 | 22 |
| Cephalexin | Cephalexin | 65 | 53 |
| Cromolyn Sodium | Cromolyn Sodium | 65 | 31 |
| Rybelsus | Semaglutide | 65 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 23 |
| Mupirocin | Mupirocin | 63 | 26 |
| Mounjaro | Tirzepatide | 57 | 15 |
| Lactulose | Lactulose | 56 | 28 |
| Trazodone Hcl | Trazodone Hcl | 55 | 26 |
| Allopurinol | Allopurinol | 53 | 18 |
| Chlorthalidone | Chlorthalidone | 51 | 17 |
| Atenolol | Atenolol | 50 | 15 |
| Ezetimibe | Ezetimibe | 50 | 18 |
| Prednisone | Prednisone | 49 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 20 |
| Montelukast Sodium | Montelukast Sodium | 48 | 15 |
| Acarbose | Acarbose | 47 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 47 | 43 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 47 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | 20 |
| Ammonium Lactate | Ammonium Lactate | 43 | 20 |
| Clotrimazole | Clotrimazole | 43 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 42 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 15 |
| Sildenafil Citrate | Sildenafil Citrate | 41 | suppressed |
| Spironolactone | Spironolactone | 40 | 17 |
| Lidocaine | Lidocaine | 39 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | suppressed |
| Pregabalin | Pregabalin | 37 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 36 | 14 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 36 | 26 |
| Buspirone Hcl | Buspirone Hcl | 36 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 35 | 18 |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 35 | 20 |
| Felodipine Er | Felodipine | 33 | suppressed |
| Hydrocortisone | Hydrocortisone | 33 | 18 |
| Diazepam | Diazepam | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | 18 |
| Sucralfate | Sucralfate | 31 | 15 |
| Terbinafine Hcl | Terbinafine Hcl | 31 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 17 |
| Xarelto | Rivaroxaban | 30 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 29 | 16 |
| Prolia | Denosumab | 28 | 21 |
| Clonazepam | Clonazepam | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Loperamide | Loperamide Hcl | 23 | 15 |
| Linzess | Linaclotide | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 20 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 12 |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 16 |
| Baclofen | Baclofen | 17 | suppressed |
| Ciclopirox | Ciclopirox | 17 | 12 |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 17 | 13 |
| Progesterone | Progesterone, Micronized | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Erythromycin | Erythromycin Base | 15 | 14 |
| Invokana | Canagliflozin | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Terconazole | Terconazole | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Procto-Med Hc | Hydrocortisone | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 11 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,584.09 · 65 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, CAPVAXIVE, COMIRNATY, ELIQUIS, EVENITY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, Fibroscan, GEMTESA, JARDIANCE, Kerendia, Korlym, MOUNJARO, OTEZLA, Ozempic, PREVNAR 20, REPATHA, Rybelsus, TZIELD, The Cologuard Plus Collection Kit, Tymlos, UBRELVY, UROLIFT, VOQUEZNA, Wegovy, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error